Artemis Investment Management LLP purchased a new position in shares of Tilray Inc (NASDAQ:TLRY) during the third quarter, HoldingsChannel.com reports. The firm purchased 45,394 shares of the company’s stock, valued at approximately $6,519,000.
Other large investors have also recently added to or reduced their stakes in the company. G&S Capital LLC purchased a new position in Tilray during the 3rd quarter worth approximately $155,000. Bank of Montreal Can purchased a new position in shares of Tilray in the 3rd quarter valued at approximately $2,467,000. Parker Investment Management LLC purchased a new position in shares of Tilray in the 3rd quarter valued at approximately $306,000. Oppenheimer & Co. Inc. purchased a new position in shares of Tilray in the 3rd quarter valued at approximately $242,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of Tilray in the 3rd quarter valued at approximately $1,123,000. Hedge funds and other institutional investors own 0.84% of the company’s stock.
Several research analysts have weighed in on the company. Cowen assumed coverage on Tilray in a research note on Monday, August 13th. They issued an “outperform” rating and a $34.00 target price on the stock. Zacks Investment Research downgraded Tilray from a “hold” rating to a “sell” rating in a research note on Tuesday, October 16th. Northland Securities downgraded Tilray from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 6th. Roth Capital reiterated a “neutral” rating on shares of Tilray in a research note on Tuesday, October 2nd. Finally, Benchmark assumed coverage on Tilray in a research note on Tuesday, October 16th. They issued a “buy” rating and a $200.00 target price on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $135.67.
Tilray (NASDAQ:TLRY) last announced its earnings results on Tuesday, November 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.08). Tilray had a negative net margin of 121.22% and a negative return on equity of 60.74%. The company had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $10.25 million. The company’s quarterly revenue was up 85.2% on a year-over-year basis. Equities analysts predict that Tilray Inc will post -0.57 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Artemis Investment Management LLP Purchases New Position in Tilray Inc (TLRY)” was published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.wkrb13.com/2018/11/23/artemis-investment-management-llp-purchases-new-position-in-tilray-inc-tlry.html.
Tilray Company Profile
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Story: How to Invest in Marijuana Stocks
Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Inc (NASDAQ:TLRY).
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.